anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The application provides a preparation method of antler slices, which comprises the following steps: s1, selecting materials, selecting the pilose antler with the advantages of good body wax, uniform, complete and fine hair. S2, softening, soaking the cornu Cervi Pantotrichum selected in S1 in Chinese liquor, and soaking the cornu Cervi Pantotrichum in the Chinese liquor by capillary action. S3, heating, and baking the cornu Cervi Pantotrichum softened by S2 in a baking oven at 50-60 deg.C for 2-3 hr. S4 slicing cornu Cervi Pantotrichum into slices after S3 heating, with thickness of 0.5-1.0 mm. S5, flattening, placing the antler slices between the pages of the moisture absorption paper one by one, pressing to flatten the antler slices, and drying. S6, packaging, and packaging according to the grade of the antler to obtain the finished product of the antler tablet. The method is simple and effective, is convenient to operate, and can reduce nutrition loss of cornu Cervi Pantotrichum in processing process and reduce loss of organic components to the maximum extent.
Tumor hypoxia has been associated with cancer progression, angiogenesis, and metastasis via modifications in the release and cargo composition of extracellular vesicles secreted by tumor cells. Indeed, hypoxic extracellular vesicles are known to trigger a variety of angiogenic responses via different mechanisms. We recently showed that hypoxia promotes endosomal signaling in tumor cells via HIF-1α-dependent induction of the guanine exchange factor ALS2, which activates Rab5, leading to downstream events involved in cell migration and invasion. Since Rab5-dependent signaling is required for endothelial cell migration and angiogenesis, we explored the possibility that hypoxia promotes the release of small extracellular vesicles containing ALS2, which in turn activate Rab5 in recipient endothelial cells leading to pro-angiogenic properties. In doing so, we found that hypoxia promoted ALS2 expression and incorporation as cargo within small extracellular vesicles, leading to subsequent transfer to recipient endothelial cells and promoting cell migration, tube formation, and downstream Rab5 activation. Consequently, ALS2-containing small extracellular vesicles increased early endosome size and number in recipient endothelial cells, which was followed by subsequent sequestration of components of the β-catenin destruction complex within endosomal compartments, leading to stabilization and nuclear localization of β-catenin. These events converged in the expression of β-catenin target genes involved in angiogenesis. Knockdown of ALS2 in donor tumor cells precluded its incorporation into small extracellular vesicles, preventing Rab5-downstream events and endothelial cell responses, which depended on Rab5 activity and guanine exchange factor activity of ALS2. These findings indicate that vesicular ALS2, secreted in hypoxia, promotes endothelial cell events leading to angiogenesis. Finally, these events might explain how tumor angiogenesis proceeds in hypoxic conditions.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic capable of applying skin massage in a state in which cosmetic is applied and enabling cleansing of skin, promotion of blood circulation and softening of skin by including a seaweed extract containing alginate and alginic acid as a film-forming agent and a water-soluble calcium salt as a curing agent. SOLUTION: (A) A seaweed extract containing an alginate (e.g. sodium alginate) and/or alginic acid is contained in an agent A as a film forming agent and (B) a curing agent comprising a water-soluble calcium salt (e.g. calcium chloride or calcium lactate) is contained in an agent B and the agent A and the agent B are contained to form a film. Preferably the component A is usually prepared as 1-20 wt.% gel-like aqueous solution in the agent A and the component B is contained in an amount of 0.5-20 wt.% in the agent B. The above cosmetic is preferably used by applying, e.g. a proper amount of the agent A to skin surface, well massaging the skin and spraying a proper amount of the agent B.
Patients, who are admitted to the Intensive Care Unit (ICU) due to septic shock in the early, acute phase. Patients are treated according to the recommendations of the Surviving Sepsis Campaign and receive xanthohumol at a dose of 2 mg per kg body weight administered via nasogastric tube as supportive therapy.
Patients receive 124I-hJAA-F11 IV on day 0. Patients then undergo PET/CT on day 1 (20-28 hours post 124I-hJAA-F11), day 2 (48-96 hours post 124I-hJAA-F11), day 5-6 (120-144 hours post 124I-hJAA-F11), and day 7-8 (168-192 hours post 124I-hJAA-F11). Patients also undergo FDG PET/CT during screening and undergo blood sample collection throughout the trial.
BACKGROUND: Prognostic relevance of differentiation grade has remained controversial in gastric adenocarcinoma (GAC) after curative resection.
METHODS: GAC patients who underwent curative gastrectomy were analyzed. Differentiation grade was evaluated according to either the most predominant or least differentiated component. Impacts of clinicopathologic parameters on postoperative recurrence and nodal metastasis were analyzed by the multivariate Cox regression analysis in pT1/2/3/4a and pT1b/2/3 GAC and by the logistic regression analysis in pT1b GAC, respectively.
RESULTS: 154 patients with GAC, consisting of 34 pT1a (recurrence rate 0%), 45 pT1b (4.4%), 18 pT2 (22.2%), 40 pT3 (35.0%), and 17 pT4a (76.5%), were included. In pT1/2/3/4a GAC, recurrence was significantly associated with only depth of invasion (pT) and grade of venous invasion (VI), although either mode of differentiation grade was significantly associated with pT by the Spearman's rank correlation test. Next, given no recurrence in pT1a and high-grade histopathology in nearly all pT4a, pT1b/2/3 GAC was analyzed, revealing that recurrence was significantly associated with only VI grade and nodal metastasis. Finally, nodal metastasis was not found in any pT1a GAC, of which 44.1% was predominantly high-grade. In pT1b GAC, nodal metastasis was irrelevant to either mode of differentiation grade, tumor size, and ulceration status but was only associated with lymphatic invasion, suggesting that endoscopic resection of pT1 GAC with negative margin can be curative even with high-grade histopathology.
CONCLUSION: Either mode of differentiation grade revealed limited prognostic relevance after curative gastrectomy. Our results may warrant a controversy over current curability evaluation of endoscopic GAC resection.
BACKGROUND: Precisely localizing the seizure onset zone (SOZ) is critical for focal epilepsy surgery. Existing methods mainly focus on high-frequency activities in stereo-electroencephalography, but often fail when seizures are not driven by high-frequency activities. Recognized as biomarkers of epileptic seizures, ictal spikes in SOZ induce epileptiform discharges in other brain regions. Based on this understanding, we aim to develop a universal algorithm to localize SOZ and investigate how ictal spikes within the SOZ induce seizures.
METHODS: We proposed a novel metric called standard deviation of spike amplitude (SDSA) and utilized channel-averaged SDSA to describe seizure processes and detect seizures. By integrating SDSA values in specific intervals, the score for each channel located within SOZ was calculated. Channels with high SOZ scores were clustered as SOZ. The localization accuracy was asserted using area under the receiver operating characteristic (ROC) curve. Further, we analyzed early ictal signals from SOZ channels and investigated factors influencing their duration to reveal the seizure inducing conditions.
RESULTS: We analyzed data from 15 patients with focal epilepsy. The channel-averaged SDSA successfully detected all 28 seizures without false alarms. Using SDSA integration, we achieved precise SOZ localization with an average area under ROC curve (AUC) of 0.96, significantly outperforming previous methods based on high-frequency activities. Further, we discovered that energy of ictal spikes in SOZ was concentrated at a specific frequency distributed in [6, 12 Hz]. Additionally, we found that the higher the energy per second in this frequency band, the faster ictal spikes could induce seizures.
CONCLUSION: The SDSA metric offered precise SOZ localization with robustness and low computational cost, making it suitable for clinical practice. By studying the propagation patterns of ictal spikes between the SOZ and non-SOZ, we suggest that ictal spikes from SOZ need to accumulate energy at a specific central frequency to induce epileptic spikes in non-SOZ, which may have significant implications for understanding the seizure onset pattern.
Couples HIV testing and counseling is completed following Centers for Disease Control and Prevention (CDC) standard protocol. Participants also complete any adjunct CHTC components associated with their originally assigned condition in NCT05000866.
Parathyroid adenomas may be identified using optical probes which distinguish the diseased tissue from adjacent healthy tissue. Spectroscopic properties of the tissue may be used to distinguish healthy from diseased tissue. Traditional surgery to remove the parathyroid adenoma may be avoided by using techniques to occlude the blood supply to the diseased tissue. Occlusion may be accomplished by applying energy to the blood vessel such as with radiofrequency energy, ultrasound energy or laser energy. Cryogenic probes may also be used to occlude the blood flow. Clips, sutures or other mechanical mechanisms may also be used to occlude the flow, thereby destroying the diseased tissue.
A resin based material whose composition includes a light-curable mixture of monomers of no more than 35 wt. % of an ethoxylated difunctional bisphenol A dimethacrylate; of no more than 10 wt. % of a methacrylate monomer; of no more than 10 wt. % of a difunctional urethane acrylate; of no more than 0.1 wt. % of an optical brightener; of no more than 5 wt. % of silica particles having methacrylate functionalization layers and having an average particle size of less than about 200 nm; of having more than 40 wt. % of an inert glass; of no more than 15 wt. % of a heavy metal oxide; of no more than 2.5 wt. % of an ultraviolet/visible (UV/Vis) light-photo- polymerization initiator; a colorant; and a stabilizer.
PURPOSE:To obtain a blood coagulation promotor for blood separation containing enzyme promoting blood coagulation at a low cost, by making HIME HABU discharge HIME HABU venom to separate it by a specified means once gathered in large amounts. CONSTITUTION:HIME HABU inhabiting in Amani and Okinawa Islands which is kept alive is made to discharge venom onto a laboratory dish to be gathered in large amounts, cooled and separated centrifugally and then, the supernatant thereof frozen dry. The matter thus dried is dissolved into a salttris buffer liquid dialyzed and then, the dialysis internal solution is separated centrifugally. After the supernatant is passed through a membrane filter, the filtrate is sent through a DE-52 cellulose-filled column. Adsorbed protein is made to elute with a linar increase in the concentration of salt in an elution liquid to obtain a fraction having no bleeding activity with a high thrombinomimetic activity. After further subjected to a biogel P-100 gel filtration twice, this fraction is dialyzed against distilled water and frozen dry. After a solution containing an stabilizing agent, antiseptic and the like is added thereto, the product undergoes an aseptic filtration and distributed into a vial to be frozen dry. Thus, a blood coagulation promotor can be obtained at a low cost.
INTRODUCTION: The pharmacological management of cancer pain is a complex issue that requires knowledge and experience in the use of analgesics. The aim of this expert review is to provide a panorama of the pharmacological strategies in cancer pain management.
AREAS COVERED: Opioid dose titration is a delicate process regarding the start of opioid treatment in different clinical conditions. How to improve the opioid response is a fundamental step, which includes different strategies when an initial treatment with opioids fails. The use of adjuvants is another relevant issue that should be considered in some specific circumstances to optimize the management of cancer pain management. Some clinical conditions, such as neuropathic pain and breakthrough pain, deserve a special attention. Relevant literature was selected to provide an overview of cancer pain management strategies.
EXPERT OPINION: Opioid therapy still remains the cornerstone of pharmacological management of cancer pain. Opioids should be used according to the level of tolerance, also personalizing the treatment (route, drug, and dosing). Adjuvant drugs may help in specific conditions, although their use should be balanced with the adverse effects. Breakthrough pain requires expertise in tailoring a treatment according to patient's profile and characteristics of episodes.
The efficacy of TECENTRIQ with carboplatin and etoposide was investigated in IMpower133 (NCT02763579), a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 403 patients with ES-SCLC. IMpower133 enrolled patients with ES-SCLC who had received no prior chemotherapy for extensive stage disease and ECOG performance status 0 or 1. The trial excluded patients with active or untreated CNS metastases, history of autoimmune disease, administration of a live, attenuated vaccine within 4 weeks prior to randomization, or administration of systemic immunosuppressive medications within 1 week prior to randomization. Randomization was stratified by sex, ECOG performance status, and presence of brain metastases. Patients were randomized to receive one of the following two treatment arms:

  * TECENTRIQ 1200 mg and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m2 intravenously on Days 1, 2 and 3 of each 21-day cycle for a maximum of 4 cycles followed by TECENTRIQ 1200 mg once every 3 weeks until disease progression or unacceptable toxicity, or
  * placebo and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m2 intravenously on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles followed by placebo once every 3 weeks until disease progression or unacceptable toxicity.



Administration of TECENTRIQ was permitted beyond RECIST-defined disease progression. Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Patients treated beyond disease progression had tumor assessment conducted every 6 weeks until treatment discontinuation.

Major efficacy outcome measures were OS and PFS as assessed by investigator per RECIST v1.1 in the intent-to-treat population. Additional efficacy outcome measures included ORR and DoR as assessed by investigator per RECIST v1.1.

A total of 403 patients were randomized, including 201 to the TECENTRIQ arm and 202 to the chemotherapy alone arm. The median age was 64 years (range 26 to 90) and 65% were male. The majority of patients were White (80%); 17% were Asian, 4% were Hispanic and 1% were Black. Baseline ECOG performance status was 0 (35%) or 1 (65%); 9% of patients had a history of brain metastases, and 97% were current or previous smokers.

Efficacy results are presented in Table 27 and Figure 6.

Figure 6: Kaplan-Meier Plot of Overall Survival in IMpower133
BACKGROUND: Cardiometabolic multimorbidity (CMM) has emerged as a prominent public health concern. Hypertensive patients are prone to develop comorbidities. Moreover, the accumulation of visceral adipose tissue is the main cause for the development of cardiometabolic diseases. The cardiometabolic index (CMI), lipid accumulation product (LAP), visceral adiposity index (VAI), and Chinese visceral adiposity index (CVAI) not only assess adipose tissue mass but also reflect adipose tissue dysfunction. So far, no study has been reported to evaluate the association of CMI, LAP, VAI, and CVAI with CMM risk in hypertensive patients. Therefore, this study aimed to assess the association between these adiposity indicators and the risk of CMM among Chinese hypertensive patients.
METHODS: In this cross-sectional study, a total of 229,287 hypertensive patients aged 35 years and older were included from the National Basic Public Health Service Project. All participants underwent a face-to-face questionnaire survey, physical examination, and the collection of fasting venous blood samples. Multivariable logistic regression models were performed to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Receiver operating characteristic curve was utilized to evaluate the identification ability for CMM.
RESULTS: After adjusting for confounders, each 1-standard deviation increase in CMI, LAP, VAI, and CVAI was associated with a 14%, 8%, 12%, and 54% increased risk of CMM, respectively. When comparing the highest quartile of these indicators with the lowest quartile, individuals in the highest quartile of CMM, LAP, VAI, and CVAI had a 1.39-fold (95% CI 1.30, 1.48), 1.28-fold (95% CI 1.19, 1.37), 1.37-fold (95% CI 1.29, 1.46), and 2.56-fold (95% CI 2.34, 2.79) increased risk of CMM after adjusting for potential confounders. Notably, a nonlinear association was observed for CMI, LAP, and VAI with the risk of CMM (all P nonlinearity < 0.001). CVAI exhibited the highest area under the receiver operating characteristic curve (AUC) among all the included adiposity indices in this analysis.
CONCLUSION: This study indicated the significant positive association of CMI, LAP, VAI, and CVAI with the risk of CMM in hypertensive patients. Among these indicators, CVAI demonstrated the most robust performance in predicting CMM risk and may serve as a valuable tool for identifying CMM risk in Chinese hypertensive patients.
BACKGROUND: Latino children in the United States (US) have a higher prevalence of overweight/obesity compared to white children. Previous studies suggest that acculturation to the US is associated with health behaviors such as diet, body mass index (BMI), and physical activity. However, the role of parental acculturation remains understudied, particularly with the use of validated measures.
OBJECTIVE: The objective of this study was to evaluate parental acculturation and its association with parental interpersonal factors and health behaviors in the preschool-aged child.
METHODS: Data were analyzed from 187 Latino parents in Nevada. Parents completed a self-reported, cross-sectional survey. Acculturation was assessed using Norris' 4-item validated acculturation measure. The average age of the preschool-aged children was 45.5 months, and their mean BMI percentile was 96.4% (SD ± 18.7). The mean parental acculturation score was 2.1 (SD ± 1.2). Children were physically active an average of 4.9 (SD ± 2.0) days per week. After controlling for covariates, the results indicated that parental acculturation was positively associated with physical activity and sugar-sweetened beverage consumption. However, parental acculturation was not associated with child BMI percentile, or the consumption of fruits, vegetables, and sweet snacks.
CONCLUSIONS: These findings can inform future research on culturally tailored intervention strategies to boost physical activity and reduce sugar-sweetened beverage intake among Latino preschool-aged children.
PURPOSE: To obtain an angiogenesis inhibitor containing fumagillin as active ingredient, and useful for preventing/treating various diseases involving the abnormal sthenia of angiogenesis in mammals such as diabetic retinopathy, ocular tumor, suppurative sarcoma, and rheumatic arthritis. CONSTITUTION: This inhibitor contains fumagillin or a pharmaceutically permissible salt thereof (e.g. sodium salt, potassium salt) as active ingredient, and pref. furthermore, angiogenesis inhibitory effect potentiator(s) such as heparin, sulfated cyclodextrin (esp. β-cyclodextrin tetradecasulfate. When to be put to use, this inhibitor can be safely administered orally or parenterally in the form of tablets or capsules or through injection. In general, the weight ratio of the potentiator to the fumagillin is about (1:10) to (3011)[pref. (1:3) to (10:1)].
Inflammatory bowel disease (IBD) is an incurable, chronic disorder of the gastrointestinal tract whose incidence increases every year. Scientific research constantly delivers new information about the disease and its multivariate, complex etiology. Nevertheless, full discovery and understanding of the complete mechanism of IBD pathogenesis still pose a significant challenge to today's science. Recent studies have unanimously confirmed the association of gut microbial dysbiosis with IBD and its contribution to the regulation of the inflammatory process. It transpires that the altered composition of pathogenic and commensal bacteria is not only characteristic of disturbed intestinal homeostasis in IBD, but also of viruses, parasites, and fungi, which are active in the intestine. The crucial function of the microbial metabolome in the human body is altered, which causes a wide range of effects on the host, thus providing a basis for the disease. On the other hand, human genomic and functional research has revealed more loci that play an essential role in gut homeostasis regulation, the immune response, and intestinal epithelial function. This review aims to organize and summarize the currently available knowledge concerning the role and interaction of crucial factors associated with IBD pathogenesis, notably, host genetic composition, intestinal microbiota and metabolome, and immune regulation.
PROBLEM TO BE SOLVED: To provide an oral preparation for preventing and treating immunopathy diseases such as rheumatoid arthritis or ulcerative colitis containing Staphylococcal-enterotoxins or their derivatives and is useful in preventing and treating these diseases. SOLUTION: This oral preparation contains Staphylococcal-enterotoxins or their derivatives, preferably in an amount of 0.02-0.5μg each dose. The enterotoxins are preferably purified at such a level that it shows a single band in the gel electrophoresis. As the enterotoxins, is preferably cited Staphylococcus aureus enterotoxins B, A, C1 , which bond to the VβT-cell antigen receptor. A liquid preparation in which the toxins or their derivatives are dissolved in physiological salt solution is preferred as an preparation form. The oral dose is 0.05-0.5μg/day on the basis of the enterotoxins and preferably given once or twice a day.
This study utilized a randomized, double-blind, placebo-controlled, within-subjects crossover design (Figure 1). Each subject was required to visit the laboratory on five occasions with 72-96 hours between sessions. During the first laboratory visit, each subject performed an incremental test on a treadmill to familiarize the subjects with the testing procedures. For the second laboratory visit, each subject performed an incremental treadmill test to exhaustion to determine their ventilatory threshold (VT). The third laboratory visit was completed in the morning (06:00-09:00) and required subjects to consume a standardized meal after fasting overnight (8 hours) and sat quietly for 30 minutes before baseline heart rate and blood pressure values were recorded. The subjects were then randomly assigned to ingest the supplement (one or two doses) or placebo and sit quietly for another 30 minutes. The ingredients of the supplement (Cellucor, Bryan, TX) are provided in Table 1. The placebo was non-energetic and controlled for similar appearance and taste. At the 15-minute and 30-minute post-ingestion periods (of the pre-workout supplement or placebo), resting heart rate and blood pressure were recorded for a second and third time, respectively. Subjects then performed a 30-minute constant-velocity treadmill run at 90% of their VT. The subjects then returned to the laboratory for their fourth and fifth visits to ingest the remaining substances (1-dose, 2-dose, or placebo) and undergo the same testing procedures (including time of day) as the third visit. Each subject recorded 2-day food logs (MyFitnessPal, Inc., USA) prior to each laboratory visit.